Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanzhong Li

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Plos One|February 4, 2015
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinomaYushi Zhang, Yongqiang Li, Jianhua Deng, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|January 28, 2016
[Analysis of clinical features of retroperitoneal bronchogenic cyst]Houfeng Huang, Guanghua Liu, Hanzhong Li, et al.
Medicine|January 11, 2017
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case reportGuoyang Zheng, Hanzhong Li, Ji Li, et al.
Experimental and Therapeutic Medicine|April 30, 2020
PTEN inhibitor VO-OHpic suppresses TSC2<sup>-</sup> <sup>/</sup> <sup>-</sup> MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathwayWenda Wang, Xu Wang, Hao Guo, et al.
Journal of Hypertension|January 7, 2010
The diagnosis and surgical management of juxtaglomerular cell tumor of the kidneyDexin Dong, Hanzhong Li, Weigang Yan, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|January 10, 2015
[Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy]Zhipeng Mai, Weigang Yan, Hanzhong Li, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 16, 2018
miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipomaYi Cai, Wenda Wang, Hao Guo, et al.
Cell Biochemistry and Biophysics|August 29, 2014
Bilateral adrenal tumors from different histology: case report and literature reviewYushi Zhang, Hanzhong Li, Jianchun Xiao, et al.
International Journal of Oncology|April 23, 2020
Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathwayYi Zhou, Zhien Zhou, Zhigang Ji, et al.
Oncology Reports|September 20, 2024
[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1Yi Zhou, Zhigang Ji, Weigang Yan, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Plos One|February 4, 2015
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinomaYushi Zhang, Yongqiang Li, Jianhua Deng, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|January 28, 2016
[Analysis of clinical features of retroperitoneal bronchogenic cyst]Houfeng Huang, Guanghua Liu, Hanzhong Li, et al.
Medicine|January 11, 2017
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case reportGuoyang Zheng, Hanzhong Li, Ji Li, et al.
Experimental and Therapeutic Medicine|April 30, 2020
PTEN inhibitor VO-OHpic suppresses TSC2<sup>-</sup> <sup>/</sup> <sup>-</sup> MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathwayWenda Wang, Xu Wang, Hao Guo, et al.
Journal of Hypertension|January 7, 2010
The diagnosis and surgical management of juxtaglomerular cell tumor of the kidneyDexin Dong, Hanzhong Li, Weigang Yan, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|January 10, 2015
[Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy]Zhipeng Mai, Weigang Yan, Hanzhong Li, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 16, 2018
miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipomaYi Cai, Wenda Wang, Hao Guo, et al.
Cell Biochemistry and Biophysics|August 29, 2014
Bilateral adrenal tumors from different histology: case report and literature reviewYushi Zhang, Hanzhong Li, Jianchun Xiao, et al.
International Journal of Oncology|April 23, 2020
Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathwayYi Zhou, Zhien Zhou, Zhigang Ji, et al.
Oncology Reports|September 20, 2024
[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1Yi Zhou, Zhigang Ji, Weigang Yan, et al.
Pageof 13